Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke
NCT04818944 · University of Iowa · PHASE1/PHASE2 · withdrawn · last registry update 2022-09-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI has left the Institution” | – | Registry record, University of Iowa |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-14Phase 3 first posted: Peking Union Medical College Hospital, Tirofiban + Aspirin tablet (NCT06037889)
- 2023-02-15Phase 3 first posted: Xinqiao Hospital of Chongqing, Tirofiban + Thrombolysis (NCT05728333)
- 2022-11-03Phase 3 first posted: Second Affiliated Hospital of Guangxi Medical University, Tirofiban Hydrochloride + Placebo (NCT05604638)
- 2021-10-04Results posted on the registry: David Hasan, tirofiban hydrochloride (AGGRASTAT®) (NCT03691727)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision